Aptose Biosciences Inc. announced updated clinical data for its lead compound tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA), presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting. The data, from the ongoing TUSCANY trial, demonstrate promising safety and antileukemic activity of the TUS+VEN+AZA regimen in newly diagnosed acute myeloid leukemia (AML) patients ineligible for induction chemotherapy. High rates of complete remission or complete remission with partial hematologic recovery (CR/CRh) were observed across multiple genetic subgroups, including those with adverse mutations such as TP53/complex karyotype, RAS, and MDS-related mutations. At the 80 mg and 120 mg TUS dose levels, a 100% response rate was reported, and 78% of responding subjects achieved minimal residual disease (MRD) negativity. No dose-limiting toxicities were observed, and safety remained consistent across cohorts. Preliminary findings from the recently initiated 160 mg dose level indicate early blast clearance and MRD-negativity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptose Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597748-en) on December 06, 2025, and is solely responsible for the information contained therein.
Comments